Stereotactic radiotherapy using Novalis for skull base metastases developing with cranial nerve symptoms

详细信息    查看全文

• 作者：Yoshimasa Mori ; Chisa Hashizume ; Tatsuya Kobayashi ; Yuta Shibamoto ; Katsura Kosaki and Aiko Nagai
• 关键词：Cranial nerve ; Metastasis ; Radiosurgery ; Skull base ; Stereotactic radiotherapy
• 刊名：Journal of Neuro-Oncology
• 出版年：2010
• 出版时间：June, 2010
• 年：2010
• 卷：98
• 期：2
• 页码：213-219
• 全文大小：420.8 KB

文摘

Skull base metastases are challenging situations because they often involve critical structures such as cranial nerves. We evaluated the role of stereotactic radiotherapy (SRT) which can give high doses to the tumors sparing normal structures. We treated 11 cases of skull base metastases from other visceral carcinomas. They had neurological symptoms due to cranial nerve involvement including optic nerve (3 patients), oculomotor (3), trigeminal (6), abducens (1), facial (4), acoustic (1), and lower cranial nerves (1). The interval between the onset of cranial nerve symptoms and Novalis SRT was 1 week to 7 months. Eleven tumors of 8–112 ml in volume were treated by Novalis SRT with 30–50 Gy in 10–14 fractions. The tumors were covered by 90–95 % isodose. Imaging and clinical follow-up has been obtained in all 11 patients for 5–36 months after SRT. Seven patients among 11 died from primary carcinoma or other visceral metastases 9–36 months after Novalis SRT. All 11 metastatic tumors were locally controlled until the end of the follow-up time or patient death, though retreatment for re-growth was done in 1 patient. In 10 of 11 patients, cranial nerve deficits were improved completely or partially. In some patients, the cranial nerve symptoms were relieved even during the period of fractionated SRT. Novalis SRT is thought to be safe and effective treatment for skull base metastases with involvement of cranial nerves and it may improve cranial nerve symptoms quickly.